These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31799437)

  • 21. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
    Gao X; Porter AT; Honn KV
    Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
    Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
    Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.
    D'Assoro AB; Leontovich A; Amato A; Ayers-Ringler JR; Quatraro C; Hafner K; Jenkins RB; Libra M; Ingle J; Stivala F; Galanis E; Salisbury JL
    Int J Oncol; 2010 Nov; 37(5):1167-76. PubMed ID: 20878064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
    Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade.
    Ding SL; Sheu LF; Yu JC; Yang TL; Chen BF; Leu FJ; Shen CY
    Br J Cancer; 2004 May; 90(10):1995-2001. PubMed ID: 15138484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
    Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
    Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma.
    Doyle B; Morton JP; Delaney DW; Ridgway RA; Wilkins JA; Sansom OJ
    J Pathol; 2010 Oct; 222(2):129-37. PubMed ID: 20662002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
    Werness BA; Parvatiyar P; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; DiCioccio RA; Wiest J; Tsukada Y; Ponder BA; Piver MS
    J Natl Cancer Inst; 2000 Jul; 92(13):1088-91. PubMed ID: 10880552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies.
    Moll UM; Ostermeyer AG; Ahomadegbe JC; Mathieu MC; Riou G
    Hum Pathol; 1995 Dec; 26(12):1293-301. PubMed ID: 8522300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CBFB cooperates with p53 to maintain TAp73 expression and suppress breast cancer.
    Malik N; Yan H; Yang HH; Ayaz G; DuBois W; Tseng YC; Kim YI; Jiang S; Liu C; Lee M; Huang J
    PLoS Genet; 2021 May; 17(5):e1009553. PubMed ID: 33945523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
    Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
    Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 pathway determines the cellular response to alcohol-induced DNA damage in MCF-7 breast cancer cells.
    Zhao M; Howard EW; Guo Z; Parris AB; Yang X
    PLoS One; 2017; 12(4):e0175121. PubMed ID: 28369097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis.
    Bado I; Nikolos F; Rajapaksa G; Wu W; Castaneda J; Krishnamurthy S; Webb P; Gustafsson JÅ; Thomas C
    Breast Cancer Res; 2017 Jul; 19(1):79. PubMed ID: 28673316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.
    Girardini JE; Napoli M; Piazza S; Rustighi A; Marotta C; Radaelli E; Capaci V; Jordan L; Quinlan P; Thompson A; Mano M; Rosato A; Crook T; Scanziani E; Means AR; Lozano G; Schneider C; Del Sal G
    Cancer Cell; 2011 Jul; 20(1):79-91. PubMed ID: 21741598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.
    Rivlin N; Katz S; Doody M; Sheffer M; Horesh S; Molchadsky A; Koifman G; Shetzer Y; Goldfinger N; Rotter V; Geiger T
    Proc Natl Acad Sci U S A; 2014 May; 111(19):7006-11. PubMed ID: 24778235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
    Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
    Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation.
    Gentile M; Bergman Jungeström M; Olsen KE; Söderkvist P; Wingren S
    Eur J Cancer; 1999 Aug; 35(8):1202-7. PubMed ID: 10615230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.